Connor Anderson @explife786 - Twitter Profile

3 days ago

The DFS lobbies are getting loud again. GPP hype is fun until the chalk crushes you. I stopped chasing last week's optimal. Build for leverage, not the crowd.

0

2

0

14

Connor Anderson @explife786

7 days ago

Who else thinks reusable coordination rails, not smarter AI, are the real bottleneck in drug development?

LIFE AI @LifeNetwork_AI

9 days ago

What kind of operational infrastructure does coordination across the healthcare value chain actually require? Eight years of building clinical programs across Southeast Asia, working with governments, hospital networks, and pharmaceutical companies, produced one consistent finding: the challenge is not the absence of capable AI. It is the absence of operational infrastructure that makes coordination reusable across programs. Without that infrastructure, coordination remains highly program-specific, especially in drug development, where multiple key players must work together across the development process. The infrastructure this requires has three properties. It has to be reusable. Clinical programs should move from bespoke projects to reusable rails, with shared coordination rails replacing bespoke integration at every site. It has to compound. Every application should strengthen the model, the network, and the protocol, building greater capacity across the ecosystem over time. It has to enable coordination among independent actors. Hospitals, doctors, labs, pharma sponsors, regulators, patients, and AI builders can contribute services, validation, and clinical execution without surrendering operational sovereignty. At Life AI, we are building an operating infrastructure for drug development around these requirements, bringing together AI-driven discovery, wet-lab screening, and clinical validation.

LifeNetwork_AI's tweet photo. What kind of operational infrastructure does coordination across the healthcare value chain actually require?

Eight years of building clinical programs across Southeast Asia, working with governments, hospital networks, and pharmaceutical companies, produced one consistent finding: the challenge is not the absence of capable AI. It is the absence of operational infrastructure that makes coordination reusable across programs.

Without that infrastructure, coordination remains highly program-specific, especially in drug development, where multiple key players must work together across the development process.

The infrastructure this requires has three properties.

It has to be reusable. Clinical programs should move from bespoke projects to reusable rails, with shared coordination rails replacing bespoke integration at every site.

It has to compound. Every application should strengthen the model, the network, and the protocol, building greater capacity across the ecosystem over time.

It has to enable coordination among independent actors. Hospitals, doctors, labs, pharma sponsors, regulators, patients, and AI builders can contribute services, validation, and clinical execution without surrendering operational sovereignty.

At Life AI, we are building an operating infrastructure for drug development around these requirements, bringing together AI-driven discovery, wet-lab screening, and clinical validation.

49

246

100

1

15K

0

1

0

7

Connor Anderson @explife786

7 days ago

But most airdrop hunters die waiting for TGE. Smart money farms testnets early, before the crowd. Retroactive rewards go to wallets with real on-chain history, not bots. Farm quietly, claim loud.